Tuesday, November 24, 2009, 5:45AM AEST - The Australian Stockmarket opens in 4 hours and 15 minutes.
To create a watchlist or portfolio of shares, Register

GlaxoSmithKline plc (GSK)

 5:30AM AEST: 41.994999 USD  Up 0.465 (1.12%)  
 MORE ON GSK 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 GLAXOSMITHKLINE PLC (NYSE:GSK) Delayed quote dataEdit
Last Trade:41.994999 USD
Trade Time: 5:30AM AEST
Change:Up 0.465 (1.12%)
Prev Close:41.529999
Open:42.470001
Bid:N/A
Ask:N/A
1y Target Est:42.15
Day's Range:41.98 - 42.700001
52wk Range:27.15 - 42.18
Volume:1,471,382
Avg Vol (3m):1,405,970
Market Cap:106.46B
P/E (ttm):13.04
EPS (ttm):3.22
Div & Yield:1.855 (4.47%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add GSK to Portfolio   Download Data

 HEADLINES 
•GlaxoSmithKline pulls application for new drug use
AP (Tue 5:21AM)
•[video] Healthcare Stocks: Safe and Speculative
at TheStreet.com (Tue 4:56AM)
•CORRECTED - Next-generation flu vaccine plant to open in U.S.
at Reuters (Tue 3:53AM)
•Barron's Magazine First Read: Dividends, VRX, DISCA
at Barrons.com (Tue 2:00AM)
•China Biotech Week in Review: CROs Consolidating
at Seeking Alpha (Mon 12:03AM)
•GlaxoSmithKline Takes 'Three-Pronged' Approach in China to Fight H1N1 Flu
at Seeking Alpha (Sun, Nov 22)
•[$$] Hot Drug Stock in Need of a Chill Pill
at Barrons.com (Sat, Nov 21)
•Big Pharma Mergers: Good News Or Bad?
Investor's Business Daily (Sat, Nov 21)
•Pfizer's Generics Business Takes Shape
at The Wall Street Journal Online (Sat, Nov 21)
•4-Star Stocks Poised to Pop: Merck
at Motley Fool (Sat, Nov 21)
•Uncertainty Breeds Opportunity in Specialty Pharma Stock Pick From Piper Jaffray Senior Research Analyst
Wall Street Transcript (Sat, Nov 21)
•Biogen's Rituxan Label Expansion Delayed
Zacks.com (Sat, Nov 21)
•Trading Review for Vivus Inc. Issued by Beacon Equity
GlobeNewswire (Fri, Nov 20)
•'Fast Money' Recap: Playing Defense
at TheStreet.com (Fri, Nov 20)
•UPDATE - US panel backs new claim for Pfizer lung drug
at Reuters (Fri, Nov 20)
More Headlines for GSK...
 ANALYST 
EPS Est (next year) (Dec-09) :3.42
EPS Est (in 2 years) (Dec-10) :3.50
Avg Rec (current)*:3.2
PEG Ratio:2.96
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health related consumer products.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
•Latest News•7 Indices